SBI2 2020 Annual Meeting Announcement
SBI2 is excited to announce that our 7th annual meeting will be held as a virtual conference. The 2020 conference will take place on the 16th-17th September, as in previous years. We are also pleased to offer this virtual experience with free registration to attendees through LabRoots, a leading scientific social networking website. More information to follow on registrations, the virtual program and poster submissions. Please follow the link below to read the full announcement from the Society President Ann Hoffman
SBI2 statement on COVID-19
The SBI2 leadership has been monitoring the 2019 coronavirus (COVID-19) situation over the past several weeks with the health and safety of our membership, students, exhibitors, partners, volunteers, and communities as the priority. We are considering information from many sources and are conscious of and support the strategy of social distancing that has been recommended/adopted to reduce unintended infection and community transmission of COVID-19 by minimizing the circumstances in which infected individuals may interact and transmit the disease.
The SBI2 BOD and Program Committee for the Annual September 2020 Conference is actively exploring resources to fulfill our mission of bringing the Conference to our members this year. As we continue to make preparations and take specific actions in this regard, we will communicate these updates to the membership.
2020 High Content Meeting Scientific Chairs and Keynote Speaker Announcement
SBI2 is excited to announce the keynote speakers for the 7th annual High Content Meeting:
Lina Nilsson Ph.D.
Senior Director of Data Science Product
Scott Fraser Ph.D.
Provost Professor of Biology & Bioengineering, Elizabeth Garrett Professor of Convergent Biosciences
Director of Science Initiatives, University of Southern California
Details on colloquium topics, program and session chairs to follow shortly. Click the 2020 Meeting page for latest information.
Board positions with Society for Biomolecular Imaging and Informatics
Positions available: President-Elect, Treasurer-Elect, Councilors
Nominations have been sent to all members via email. If you have not received this notification please email Info@SBI2.org
Voting deadline: December 9, 2019
High Content 2019 Program Announced
SBI2 are excited to announce the keynote speakers for the High Content 2019 meeting: Aviv Regev and Chee-Yeun Chung. Details of the educational courses with topics including image analysis and machine learning have also been released. This years colloquium will be focused on Cell Painting for Drug Discovery. Click below for details
SBI2 annual meeting keynote alumni Brenda Andrews elected as a foreign associate of the National Academy of Sciences
SBI2 Congratulates the 2017 Annual Meeting keynote alumni Brenda Andrews who was elected as a foreign associate of the National Academy of Sciences. Click the link below for more information
SBI2 and SLAS 2020 HCS/HCA Data and Informatics Special Interest Group
For the 7th year the Society of Biomolecular Imaging and Informatics (SBI2) and SLAS will co-host the HCS/HCA Data and Informatics Special Interest Group (SIG). SLAS 2020, Wednesday, January 29th, 2020 https://www.slas2020.org
2019 Functional High Throughput Technologies Australia Meeting
The SBI2 supported conference FHTTA, has now released its 2019 meeting program. The 10th annual meeting will be held on October 30-31st at the John Curtin School of Medical Research at the ANU in Canberra. Click website for registration details FHTTA.com
Sponsors of The 2019 Meeting
SBI2 is please to announce the official sponsors and exhibitors of the 2019 High Content Meeting in Boston.
READ NOW: SBI2 SPECIAL ISSUE OF ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
Myles Fennell, PhD and Kaylene J. Simpson, PhD
The Society of Biomolecular Imaging and Informatics (SBI2) is an international community promoting high-content imaging at all stages of experimental development, technological advancement, and discovery. For the fourth year running, SBI2 has teamed up with ASSAY and Drug Development Technologies to publish a series of research articles on HCS and high-content analysis (HCA).